SCHEMBL7175458

SCHEMBL7175458

COc1cc(OC)c(C(=O)P(=O)(C(=O)c2c(Cl)cccc2Cl)c2ccccc2)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 3/20 0.46
MAPT P10636 3/20 0.41
KMT2A Q03164 3/20 0.41
ATM Q13315 2/20 0.41
CYP3A4 P08684 2/20 0.41
TP53 P04637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ELANE P08246 1/20 0.40
TOP1 P11387 1/20 0.39
POLB P06746 3/20 0.39
NPC1 O15118 2/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
GAA P10253 1/20 0.39
PTK2B Q14289 1/20 0.39
PTGS2 P35354 2/20 0.38
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175981 0.95 ABCG2 (0.44) ABCG2MAPTKMT2AATMCYP3A4
SCHEMBL7180575 0.93 ABCG2 (0.42) ABCG2MAPTKMT2AATMCYP3A4
SCHEMBL7184054 0.91 ABCG2 (0.42) ABCG2MAPTKMT2AATMCYP3A4
SCHEMBL2768729 0.91 KMT2A (0.47) ABCG2MAPTKMT2AATMCYP3A4
SCHEMBL7180921 0.90 ABCG2 (0.41) ABCG2MAPTKMT2AATMCYP3A4
SCHEMBL7177647 0.90 PTGS2 (0.41) MAPTKMT2ATOP1POLBNPC1
SCHEMBL7188964 0.89 MAPT (0.48) ABCG2MAPTKMT2AATMCYP3A4
SCHEMBL7186465 0.89 CA12 (0.47) MAPTGAAPTK2BPTGS2GRM4
SCHEMBL7183286 0.89 ALDH1A1 (0.47) ABCG2MAPTKMT2AATMCYP3A4
SCHEMBL7178118 0.89 ABCG2 (0.42) ABCG2MAPTKMT2AATMCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ABCG2 3732/4885MAPT 4870/4885KMT2A 1586/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ABCG2 4323/4885MAPT 4859/4885KMT2A 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.